vs
Side-by-side financial comparison of IRONWOOD PHARMACEUTICALS INC (IRWD) and INVESTORS TITLE CO (ITIC). Click either name above to swap in a different company.
INVESTORS TITLE CO is the larger business by last-quarter revenue ($69.5M vs $47.7M, roughly 1.5× IRONWOOD PHARMACEUTICALS INC). On growth, INVESTORS TITLE CO posted the faster year-over-year revenue change (-1.6% vs -47.3%). IRONWOOD PHARMACEUTICALS INC produced more free cash flow last quarter ($74.6M vs $25.4M). Over the past eight quarters, INVESTORS TITLE CO's revenue compounded faster (14.0% CAGR vs -20.2%).
Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc.
The Real Estate Title Insurance Company of Philadelphia was the world's first title insurance company.
IRWD vs ITIC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $47.7M | $69.5M |
| Net Profit | $-2.3M | — |
| Gross Margin | — | — |
| Operating Margin | 14.3% | 13.8% |
| Net Margin | -4.8% | — |
| Revenue YoY | -47.3% | -1.6% |
| Net Profit YoY | -200.9% | — |
| EPS (diluted) | $0.01 | $3.97 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $47.7M | $69.5M | ||
| Q3 25 | $122.1M | $73.0M | ||
| Q2 25 | $85.2M | $73.6M | ||
| Q1 25 | $41.1M | $56.6M | ||
| Q4 24 | $90.5M | $70.6M | ||
| Q3 24 | $91.6M | $68.8M | ||
| Q2 24 | $94.4M | $65.4M | ||
| Q1 24 | $74.9M | $53.5M |
| Q4 25 | $-2.3M | — | ||
| Q3 25 | $40.1M | $12.2M | ||
| Q2 25 | $23.6M | $12.3M | ||
| Q1 25 | $-37.4M | $3.2M | ||
| Q4 24 | $2.3M | — | ||
| Q3 24 | $3.6M | $9.3M | ||
| Q2 24 | $-860.0K | $8.9M | ||
| Q1 24 | $-4.2M | $4.5M |
| Q4 25 | 14.3% | 13.8% | ||
| Q3 25 | 61.8% | 20.7% | ||
| Q2 25 | 53.2% | 21.5% | ||
| Q1 25 | -70.7% | 7.2% | ||
| Q4 24 | 34.8% | 15.3% | ||
| Q3 24 | 28.0% | 16.8% | ||
| Q2 24 | 26.5% | 17.2% | ||
| Q1 24 | 14.7% | 10.8% |
| Q4 25 | -4.8% | — | ||
| Q3 25 | 32.8% | 16.7% | ||
| Q2 25 | 27.7% | 16.7% | ||
| Q1 25 | -90.9% | 5.6% | ||
| Q4 24 | 2.5% | — | ||
| Q3 24 | 4.0% | 13.5% | ||
| Q2 24 | -0.9% | 13.6% | ||
| Q1 24 | -5.6% | 8.5% |
| Q4 25 | $0.01 | $3.97 | ||
| Q3 25 | $0.23 | $6.45 | ||
| Q2 25 | $0.14 | $6.48 | ||
| Q1 25 | $-0.23 | $1.67 | ||
| Q4 24 | $0.03 | $4.41 | ||
| Q3 24 | $0.02 | $4.92 | ||
| Q2 24 | $-0.01 | $4.70 | ||
| Q1 24 | $-0.03 | $2.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $215.5M | $89.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-261.8M | $268.3M |
| Total Assets | $396.9M | $363.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $215.5M | $89.6M | ||
| Q3 25 | $140.4M | $110.8M | ||
| Q2 25 | $92.9M | $90.1M | ||
| Q1 25 | $108.5M | $81.7M | ||
| Q4 24 | $88.6M | $83.8M | ||
| Q3 24 | $88.2M | $112.9M | ||
| Q2 24 | $105.5M | $111.2M | ||
| Q1 24 | $121.5M | $135.0M |
| Q4 25 | — | — | ||
| Q3 25 | $199.5M | — | ||
| Q2 25 | $199.3M | — | ||
| Q1 25 | $199.2M | — | ||
| Q4 24 | $199.0M | — | ||
| Q3 24 | $198.8M | — | ||
| Q2 24 | $198.6M | — | ||
| Q1 24 | $398.3M | — |
| Q4 25 | $-261.8M | $268.3M | ||
| Q3 25 | $-264.2M | $278.0M | ||
| Q2 25 | $-308.2M | $266.2M | ||
| Q1 25 | $-334.1M | $254.4M | ||
| Q4 24 | $-301.3M | $251.8M | ||
| Q3 24 | $-311.3M | $271.3M | ||
| Q2 24 | $-321.7M | $261.8M | ||
| Q1 24 | $-330.5M | $254.0M |
| Q4 25 | $396.9M | $363.1M | ||
| Q3 25 | $396.1M | $363.3M | ||
| Q2 25 | $342.9M | $345.8M | ||
| Q1 25 | $327.2M | $333.8M | ||
| Q4 24 | $350.9M | $333.6M | ||
| Q3 24 | $389.5M | $352.0M | ||
| Q2 24 | $395.6M | $340.3M | ||
| Q1 24 | $438.8M | $329.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $74.6M | $30.9M |
| Free Cash FlowOCF − Capex | $74.6M | $25.4M |
| FCF MarginFCF / Revenue | 156.3% | 36.5% |
| Capex IntensityCapex / Revenue | 0.0% | 8.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $127.0M | $47.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $74.6M | $30.9M | ||
| Q3 25 | $47.6M | $17.2M | ||
| Q2 25 | $-15.1M | $8.9M | ||
| Q1 25 | $20.0M | $-75.0K | ||
| Q4 24 | $15.2M | $29.8M | ||
| Q3 24 | $9.9M | $7.8M | ||
| Q2 24 | $33.5M | $8.4M | ||
| Q1 24 | $45.0M | $1.4M |
| Q4 25 | $74.6M | $25.4M | ||
| Q3 25 | $47.6M | $15.8M | ||
| Q2 25 | $-15.1M | $7.3M | ||
| Q1 25 | $19.9M | $-1.4M | ||
| Q4 24 | — | $22.4M | ||
| Q3 24 | $9.9M | $6.1M | ||
| Q2 24 | $33.4M | $6.3M | ||
| Q1 24 | $44.9M | $-793.0K |
| Q4 25 | 156.3% | 36.5% | ||
| Q3 25 | 39.0% | 21.7% | ||
| Q2 25 | -17.7% | 9.9% | ||
| Q1 25 | 48.4% | -2.5% | ||
| Q4 24 | — | 31.7% | ||
| Q3 24 | 10.8% | 8.8% | ||
| Q2 24 | 35.4% | 9.7% | ||
| Q1 24 | 60.0% | -1.5% |
| Q4 25 | 0.0% | 8.0% | ||
| Q3 25 | 0.0% | 1.8% | ||
| Q2 25 | 0.0% | 2.1% | ||
| Q1 25 | 0.1% | 2.4% | ||
| Q4 24 | 0.0% | 10.5% | ||
| Q3 24 | 0.0% | 2.5% | ||
| Q2 24 | 0.1% | 3.2% | ||
| Q1 24 | 0.1% | 4.2% |
| Q4 25 | — | — | ||
| Q3 25 | 1.19× | 1.40× | ||
| Q2 25 | -0.64× | 0.72× | ||
| Q1 25 | — | -0.02× | ||
| Q4 24 | 6.74× | — | ||
| Q3 24 | 2.71× | 0.84× | ||
| Q2 24 | — | 0.95× | ||
| Q1 24 | — | 0.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
